
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab is seeing positive results from its EPCORE DLBCL trials for EPKINLY, with statistically significant and clinically meaningful improvement in PFS. This, combined with the drug's accelerated approval and strong data in phase 2 trials, leads to a high probability of approval in 1L and 2L+ DLBCL settings. With these developments in mind, and after accounting for potential costs related to acquisitions and integration, the outlook for Genmab's stock is positive with a Buy rating and a price target of $40, up from the previous $38.
Bears say
Genmab is likely to experience a decline in profits due to the high levels of acquisition and integration charges compared to previous quarters. The company's heavy reliance on partner products like Darzalex and Tepezza also raises concerns about potential fluctuations in revenue and profitability in the future. Additionally, the competition in the biotechnology industry and the uncertainty surrounding FDA approvals could add further risk to Genmab's stock.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares